Brotizolam M Uses, Dosage, Side Effects and more
Brotizolam M is a sedative-hypnotic thienodiazepine drug which is a benzodiazepine analog. It demonstrates anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant effects. Brotizolam M has similar effects to short-acting benzodiazepines such as triazolam. Brotizolam M is indicated for 2-4 weeks of treatment for severe or debilitating insomnia. Brotizolam M is an extremely potent drug and it is rapidly eliminated with an average half-life of 4.4 hours (range 3.6 - 7.9 hours).
Brotizolam M is not approved for sale in the UK, United States or Canada but is sold in the Netherlands, Germany, Spain, Belgium, Austria, Portugal, Israel, Italy and Japan.
| Attribute | Details |
|---|---|
| Trade Name | Brotizolam M |
| Generic | Brotizolam |
| Brotizolam Other Names | Brotizolam, Brotizolamum |
| Type | |
| Formula | C15H10BrClN4S |
| Weight | Average: 393.689 Monoisotopic: 391.949807384 |
| Protein binding | The mean value of the free fraction (%): 8.4 ± 0.7. |
| Groups | Investigational, Withdrawn |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Brotizolam M is a benzodiazepine analogue with sedative-hypnotic properties used for short-term treatment of severe or debilitating insomnia.
Brotizolam M is indicated for 2-4 weeks in the treatment of severe or debilitating insomnia.
Brotizolam M is also used to associated treatment for these conditions: Insomnia
Volume of Distribution
0.63 l/kg.
Elimination Route
The plasma concentration profile of brotizolam can be described as a one compartmental open model with first-order absorption.
Half Life
4.4 hours.
Clearance
Total clearance: 109 ml/min.
